Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2012

View Archived Issues

Allergan presents new S1P1 receptor ligands

Randomized trial shows benefit of armodafinil in patients with traumatic brain injury

Phase I/Ib trial evaluates AUY-922 alone and with bortezomib

Encouraging phase II results presented on PD-0332991

New LDL-PLA2 inhibitors developed by GlaxoSmithKline

Italian researchers disclose novel EP4 receptor antagonists

Roche divulges novel Mdm2/p53 interaction inhibitors

Chinese group reports new antivirals

U.S. university patents new polypeptides

Epizyme synthesizes novel DOT1-like protein inhibitors

Amitiza approved in Japan

Debio-0932 shows promising activity in patients with advanced solid tumors

Sirnaomics plans siRNA-based therapeutic study in China

Ultragenyx begins dosing in new UX-001 study

Pfizer grants ChemRar rights to DPP IV inhibitor

Prosonix and Imperial College London to collaborate on engineered combination respiratory medicines

FDA accepts Adasuve NDA resubmission

Optimer obtains approval in Canada for CDI treatment

Health Canada approves Jakavi for treatment of patients with myelofibrosis

New models of kidney cancer developed in U.S.

MK-6096 effective in multinational trial

Companies file application in Japan for oral imaging agent for malignant glioma

FDA approves first test for quantifying CMV DNA in human plasma

Amgen completes acquisition

New public-private partnership aims to develop pediatric formulation of schistosomiasis treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...